Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Tobira Pharmaceuticals, Inc. (“Tobira” or the “Company”) (NASDAQ CM: TBRA) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Allergan plc (“Allergan”) (NYSE: AGN), in a transaction valued at approximately $1.695 billion.
Click here to learn more: http://rigrodskylong.com/investigations/tobira-pharmaceuticals-inc-tbra.
Under the terms of the agreement, shareholders of Tobira will receive an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for each share of Tobira common stock.
The investigation concerns whether Tobira’s board of directors failed to adequately shop the Company and obtain the best possible value for Tobira shareholders before entering into an agreement with Allergan.
If you own the common stock of Tobira and purchased your shares before September 20, 2016, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to email@example.com, or at: http://rigrodskylong.com/investigations/tobira-pharmaceuticals-inc-tbra.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920006466/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.